10-Q: BMS Q3 Earnings Surge on Growth Portfolio, Strategic Pipeline Expansion

Bristol-Myers Squibb reported a significant increase in Q3 net earnings and diluted EPS, driven by strong performance in its Growth Portfolio and strategic business development activities, despite ongoing generic erosion of legacy products.

Summary

• Net earnings attributable to BMS increased 82% to $2.201 billion for Q3 2025, and turned around from a loss of $9.020 billion to a gain of $5.967 billion year-to-date 2025.
• Diluted GAAP EPS rose 80% to $1.08 for Q3 2025, and significantly improved from a loss of $4.45 to a gain of $2.93 year-to-date 2025.
• Total revenues increased 3% to $12.222 billion for Q3 2025, but decreased 1% to $35.692 billion year-to-date 2025.
• The Growth Portfolio saw an 18% revenue increase in Q3 2025 to $6.857 billion, with strong performances from Reblozyl (+37%), Breyanzi (+60%), and Camzyos (+89%).
• Legacy Portfolio revenues declined 12% in Q3 2025 to $5.365 billion, primarily due to generic erosion of Revlimid (-59%), Sprycel (-59%), and Abraxane (-71%).
• Amortization of acquired intangible assets decreased significantly by 65% in both Q3 and year-to-date 2025, largely due to Revlimid's acquired marketed product right being fully amortized in Q4 2024.
• The company is pursuing a strategic productivity initiative, expecting $2.0 billion in annual cost savings by the end of 2027.
• Significant business development activities include the planned acquisition of Orbital Therapeutics for $1.5 billion, a collaboration with BioNTech for pumitamig ($1.5 billion upfront), and licensing deals with Philochem ($350 million upfront) and BioArctic ($100 million upfront).

Sentiment

Score: 8

Explanation: The company demonstrated strong GAAP earnings growth for the quarter and a significant turnaround year-to-date, driven by robust performance in its Growth Portfolio and substantial reductions in amortization expenses. Strategic business development activities are actively expanding the pipeline. While legacy products face generic erosion and regulatory pricing pressures are a concern, the overall financial health and strategic direction appear positive and proactive.

Positives

• Net earnings attributable to BMS increased 82% to $2.201 billion for the three months ended September 30, 2025, compared to $1.211 billion in the prior year.
• Diluted GAAP EPS increased 80% to $1.08 for the three months ended September 30, 2025, up from $0.60 in the prior year.
• Year-to-date net earnings attributable to BMS significantly improved to $5.967 billion in 2025, compared to a loss of $9.020 billion in 2024.
• Year-to-date diluted GAAP EPS improved to $2.93 in 2025, compared to a loss of $4.45 in 2024.
• The Growth Portfolio revenues increased 18% to $6.857 billion in Q3 2025, driven by strong demand for key products.
• Reblozyl revenue grew 37% to $615 million in Q3 2025, and 35% year-to-date to $1.661 billion.
• Breyanzi revenue surged 60% to $359 million in Q3 2025, and 100% year-to-date to $966 million, driven by new indication launches and market expansion.
• Camzyos revenue increased 89% to $296 million in Q3 2025, and 88% year-to-date to $714 million, due to higher demand.
• Eliquis revenue increased 25% to $3.746 billion in Q3 2025, and 8% year-to-date to $10.991 billion, primarily due to higher demand.
• Amortization of acquired intangible assets decreased by $1.6 billion in Q3 2025 and $4.7 billion year-to-date, primarily due to the full amortization of the Revlimid acquired marketed product right in Q4 2024.
• Selling, general and administrative expenses decreased by $194 million in Q3 2025 and $1.2 billion year-to-date, reflecting cost savings from the strategic productivity initiative.
• The company expects $2.0 billion in annual cost savings by the end of 2027 from its strategic productivity initiative.
• Multiple regulatory approvals were achieved in 2025, including Breyanzi for FL in the EU, Camzyos for oHCM in Japan, and Opdivo + Yervoy for HCC and MSI-H/dMMR CRC in the U.S. and EU.
• Label updates from the FDA reduced or removed certain patient monitoring requirements for Camzyos, Breyanzi, and Abecma.
• Strategic pipeline expansion through the planned acquisition of Orbital Therapeutics for OTX-201, a collaboration with BioNTech for pumitamig, and licensing deals with Philochem for OncoACP3 and BioArctic for Alzheimer's programs.
• Opened a new radiopharmaceutical facility in Indianapolis, expanding development and manufacturing capabilities for RPTs.

Negatives

• Total revenues decreased 1% year-to-date to $35.692 billion, primarily due to the impact of generics on the Legacy Portfolio and the redesign of the U.S. Medicare Part D program.
• Legacy Portfolio revenues decreased 12% in Q3 2025 and 16% year-to-date, largely due to generic erosion.
• Revlimid revenue declined 59% in Q3 2025 to $575 million and 47% year-to-date to $2.349 billion, due to generic competition and lower net selling prices.
• Pomalyst/Imnovid revenue decreased 25% in Q3 2025 to $675 million and year-to-date to $2.041 billion, primarily due to lower average net selling prices impacted by the Medicare Part D program redesign.
• Sprycel revenue fell 59% in Q3 2025 to $119 million and 62% year-to-date to $413 million, due to generic erosion.
• Abraxane revenue dropped 71% in Q3 2025 to $74 million and 59% year-to-date to $284 million, due to generic erosion.
• Abecma U.S. revenues decreased 34% in Q3 2025 and 15% year-to-date, attributed to increased competition in BCMA targeted therapies.
• Acquired IPRD charges increased 142% in Q3 2025 to $633 million, primarily due to the BioNTech upfront fee ($1.5 billion year-to-date) and SystImmune milestone ($250 million in Q3).
• Non-GAAP diluted EPS decreased 9.4% to $1.63 for Q3 2025, primarily due to higher one-time Acquired IPRD charges.
• The Phase III INDEPENDENCE trial for Reblozyl in myelofibrosis-associated anemia did not meet its primary endpoint of RBC transfusion independence.
• An $85 million IPRD impairment charge was recorded in Q3 2025 for an oncology asset due to pipeline reprioritization, and a partial write-down of another oncology asset.

Risks

• Increased pricing pressure and other restrictions in the U.S. and abroad continue to negatively affect revenues and profit margins, stemming from legislative and policy changes, price controls, market access, discounting, and changes to tax and importation laws.
• Eliquis has been selected for 'maximum fair price' by the HHS, effective January 1, 2026, which applies to the U.S. Medicare channel.
• Pomalyst has been selected for 'negotiation' for government-set prices beginning in 2027.
• More products could be selected for government price setting in future years, potentially accelerating revenue erosion prior to intellectual property expiry.
• The IRA's redesign of the U.S. Medicare Part D program requires manufacturers to be responsible for 10% of costs up to the $2,000 cap and 20% after that cap, impacting revenues and GTN adjustments.
• The 'Delivering Most-Favored Nation Prescription Drug Pricing to American Patients' executive order could result in reduced prices and reimbursement for certain U.S. products.
• Ongoing litigation related to patent infringement for Eliquis in Europe, with generics already on the market in some countries (e.g., UK, Finland, Poland, Portugal).
• Patent infringement actions against generic manufacturers for Pomalyst and Zeposia in the U.S. are ongoing, with some settlements and some pending trials.
• Securities litigation (Celgene Securities Class Action, CVR Litigations) and other antitrust litigation (Thalomid and Revlimid, Pomalyst) pose potential financial liabilities and reputational risks.
• BMS lost appeals in the IRA Litigation and 340B Litigation, challenging government drug pricing programs, which could have material impacts on business and results of operations.
• The company is under examination by tax authorities (e.g., IRS for 2008-2012 tax years) that proposed or are considering proposing material adjustments to tax positions, with potential decreases in unrecognized tax benefits of $260 million to $300 million in the next twelve months.
• Difficulties, delays, and disruptions in the supply chain, manufacturing, distribution, and sale of products.
• Changes to tax regulations could negatively impact earnings.

Future Outlook

The company aims to combine the resources of a large pharmaceutical company with the agility of biotech, focusing on transformational medicines in oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. It plans to drive commercial execution of key first-in-class/best-in-class products and expand its pipeline through internal R&D and business development. The ongoing strategic productivity initiative is expected to yield $2.0 billion in annual cost savings by the end of 2027. The company continues to assess the full scope and potential commercial implications of new tax legislation (OBBBA) and drug pricing regulations (IRA, Most-Favored Nation), which could impact cash flows and results of operations.

Management Comments

• Our principal strategy is to combine the resources, scale and capability of a large pharmaceutical company with the speed, agility and focus on innovation typically found in the biotech industry.
• Our priorities are to focus on transformational medicines where we have a competitive advantage, drive operational excellence and strategically allocate capital for long-term growth and shareholder returns.
• We are driving commercial execution in our key first-in-class and/or best-in-class marketed products, where we continue to expand and see potential for further expansion into the future.
• We remain committed to the strategic allocation of resources and investing in areas that maximize value and drive sustainable growth.
• We expect to reclassify pre-tax losses of $130 million into Cost of products sold for the Company's foreign currency exchange contracts out of AOCL during the next 12 months.
• It is reasonably possible that the amount of unrecognized tax benefits as of September 30, 2025 could decrease in the range of approximately $260 million to $300 million in the next twelve months as a result of the settlement of certain tax audits and other events.
• We believe that our existing cash, cash equivalents and marketable debt securities, together with our ability to generate cash from operations and our access to short-term and long-term borrowings, are sufficient to satisfy our existing and anticipated cash needs.

Industry Context

The pharmaceutical industry is facing increasing pressure from governmental actions, including price controls, market access restrictions, and changes to tax and importation laws in the U.S., EU, and other regions. These pressures are leading to lower prices, reduced reimbursement rates, and smaller patient populations for whom payers will reimburse. The Inflation Reduction Act (IRA) and the 'Most-Favored Nation' executive order are significant regulatory headwinds, with Eliquis and Pomalyst already targeted for price setting/negotiation. Despite these challenges, the industry continues to see strong demand for innovative medicines, particularly in oncology and immunology, driving companies like BMS to invest heavily in R&D, strategic collaborations, and acquisitions to replenish pipelines and maintain growth amidst generic erosion of older, high-revenue products. The shift towards specialized therapies like CAR T-cell and radiopharmaceuticals is a key trend.

Comparison to Industry Standards

• The company's strategy to combine large pharma resources with biotech agility is a common approach in the industry to foster innovation while leveraging scale.
• The significant revenue growth in newer 'Growth Portfolio' products like Reblozyl, Breyanzi, and Camzyos demonstrates successful product launches and market penetration, comparable to other leading biopharmaceutical companies introducing novel therapies.
• The decline in 'Legacy Portfolio' revenues due to generic erosion (e.g., Revlimid, Sprycel, Abraxane) is a standard lifecycle challenge for pharmaceutical companies, necessitating continuous pipeline replenishment.
• The impact of the U.S. Medicare Part D redesign and government price-setting initiatives (IRA) on Eliquis and Pomalyst reflects a broader industry-wide challenge that all major pharmaceutical companies with high-revenue drugs face in the U.S. market.
• The active pursuit of strategic collaborations and acquisitions (e.g., BioNTech, Orbital Therapeutics, Philochem, BioArctic) is a standard industry practice for expanding R&D capabilities and product pipelines, especially in high-growth areas like oncology, autoimmune, and neuroscience.
• The IPRD impairment charges and the failure of the Reblozyl INDEPENDENCE trial are inherent risks in pharmaceutical R&D, common across the industry, highlighting the high-risk, high-reward nature of drug development.
• The increased competition for Abecma in BCMA targeted therapies indicates a rapidly evolving and competitive landscape in cell therapy, where companies like Johnson & Johnson (Carvykti) and Regeneron (Odronextamab) are also active.

Legal Proceedings

• Eliquis Europe: Ongoing litigations against generic apixaban products in multiple European countries. Final negative decision in the UK led to generics entering the market. Final positive decisions in Norway, Spain, Sweden, Switzerland, France, Belgium, and the Netherlands. Initial negative decisions in Finland, Ireland, and Slovakia (appeals pending). Generics have entered the market in Finland, Poland, and Portugal while proceedings are pending.
• Pomalyst U.S.: Patent infringement actions against Cipla, USV, Deva, and Sandoz for generic pomalidomide products. Settlements reached with Cipla (September 2025), Deva (August 2025), and USV (October 2025). Case against Sandoz remains pending.
• Zeposia U.S.: Patent infringement actions against Synthon and Apotex for generic ozanimod products. Settlement reached with Synthon (September 2025). Apotex case remains pending with trial scheduled for February 2027.
• Celgene Securities Litigations: A settlement in principle was reached in September 2025 to resolve the Celgene Securities Class Action, subject to court approval. Individual actions with similar allegations are consolidated for pre-trial proceedings, with partial summary judgment granted to defendants in August 2025.
• Contingent Value Rights Litigations: Multiple ongoing lawsuits alleging breaches of the CVR Agreement related to the Celgene acquisition. BMS's motion to dismiss one case for lack of subject matter jurisdiction was granted in September 2024, but the plaintiff appealed and filed a new lawsuit. BMS has filed motions to dismiss the new complaints.
• IRA Litigation: BMS's lawsuit challenging the constitutionality of the IRA's drug-pricing program. The Third Circuit affirmed the lower court's decision against BMS in September 2025.
• 340B Litigation: BMS's lawsuit challenging HRSA's determination on the 340B drug pricing program. The U.S. District Court granted HRSA summary judgment in May 2025, and BMS has appealed, with oral argument scheduled for November 2025.
• Thalomid and Revlimid Litigations: Putative class action lawsuits alleging antitrust, consumer protection, and unfair competition violations. Certain complaints were dismissed with leave to amend in June 2024, and amended complaints were filed in August 2024, with motions to dismiss pending.
• Pomalyst Antitrust Class Action: Putative class actions alleging antitrust violations. Complaints against Celgene, BMS, and individuals were dismissed in March 2025, with plaintiffs seeking leave to amend. An additional plaintiff filed a similar suit in June 2025.
• Environmental Proceedings: BMS is responsible for costs of investigating and/or remediating contamination at current or former sites or waste disposal facilities, with an estimated share of future costs of $60 million as of September 30, 2025.

Stakeholder Impact

• Shareholders: Positive impact from increased GAAP net earnings and EPS, strong growth in the Growth Portfolio, and planned cost savings. Potential negative impact from generic erosion of legacy products and ongoing litigation risks. Share repurchase program provides support.
• Patients: Positive impact from new regulatory approvals for products like Breyanzi, Camzyos, Opdivo + Yervoy, and Augtyro, expanding treatment options. Potential negative impact from the failure of the Reblozyl INDEPENDENCE trial for myelofibrosis-associated anemia.
• Employees: Impacted by the 2023 Restructuring Plan, which involves evolving and streamlining the operating model, potentially leading to employee termination costs.
• Customers/Payers: Impacted by governmental drug pricing programs (IRA, Most-Favored Nation) which could lead to lower prices and reimbursement rates for certain BMS products.
• Alliance Partners: BioNTech, SystImmune, Philochem, BioArctic benefit from upfront payments, milestones, and profit-sharing/royalties from collaborations.

Next Steps

• Close the acquisition of Orbital Therapeutics in Q4 2025.
• Continue development and commercialization of pumitamig with BioNTech.
• Continue research, development, manufacturing, and commercialization of OncoACP3 with Philochem.
• Continue development and commercialization of PyroGlutamate-amyloid-beta antibody program with BioArctic.
• Continue to implement the 2023 Restructuring Plan to achieve $2.0 billion in annual cost savings by the end of 2027.
• Monitor and respond to ongoing legal proceedings, including patent infringement cases and antitrust litigations.
• Continue to assess the impact of the IRA and other governmental drug pricing initiatives.
• FDA PDUFA goal date of December 5, 2025, for Breyanzi sBLA for MZL.
• FDA PDUFA goal date of March 6, 2026, for Sotyktu sNDA for psoriatic arthritis.
• Oral argument scheduled for November 2025 in the 340B Litigation appeal.
• BioNTech anniversary payments of $2.0 billion in aggregate will be payable beginning in 2026 through 2028.
• Generic pomalidomide products are expected to enter the U.S. market in March 2026.
• Revlimid generic licenses will no longer be volume limited in the U.S. beginning on January 31, 2026.
• Trial scheduled for February 2027 for the Apotex case regarding Zeposia.

Key Dates

Recommendation

Bristol-Myers Squibb's Q3 2025 results demonstrate a strong financial turnaround, with significant increases in GAAP net earnings and EPS, largely driven by the successful performance of its Growth Portfolio and the substantial reduction in amortization expenses following the full amortization of Revlimid's intangible assets. The company is actively managing its portfolio transition, investing heavily in strategic acquisitions and collaborations to replenish its pipeline in high-growth therapeutic areas like oncology, autoimmune, and neuroscience. While facing ongoing challenges from generic erosion of legacy products and increasing governmental pricing pressures, the proactive cost-saving initiatives and robust pipeline development indicate a resilient and forward-looking strategy. The positive momentum in key growth brands and the strategic focus on innovation position BMS favorably for long-term value creation, making it an attractive investment for a seasoned investor.

Keywords

Pharmaceuticals, Biotechnology, Oncology, Immunology, Cardiovascular, Neuroscience, SEC Filing, Earnings Report, Drug Development, Pipeline, Acquisitions, Strategic Alliances, Patent Expiry, Generic Competition, Drug Pricing, Medicare Part D, Opdivo, Eliquis, Revlimid, Reblozyl, Breyanzi, Camzyos, Zeposia, Abecma, Sotyktu, Krazati, Pomalyst, Sprycel, Abraxane, Orbital Therapeutics, BioNTech, Philochem, BioArctic, Radiopharmaceutical, CAR T-cell therapy, RNA medicines, Schizophrenia, Multiple Myeloma, NSCLC, HCC, Psoriatic Arthritis, Myelofibrosis, Alzheimer's Disease, Autoimmune Disease, Clinical Trials, Regulatory Approval, Financial Performance, Revenue Growth, EPS, Cost Savings, Litigation, Intellectual Property